Home » Stocks » CTXR

Citius Pharmaceuticals, Inc. (CTXR)

Stock Price: $1.26 USD 0.01 (0.80%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Pre-market: $1.27 +0.01 (0.79%) Jan 25, 5:17 AM
Market Cap 70.03M
Revenue (ttm) n/a
Net Income (ttm) -17.55M
Shares Out 39.17M
EPS (ttm) -0.45
PE Ratio n/a
Forward PE 1.29
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $1.26
Previous Close $1.25
Change ($) 0.01
Change (%) 0.80%
Day's Open 1.29
Day's Range 1.21 - 1.30
Day's Volume 790,774
52-Week Range 0.45 - 1.51

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 month ago

CRANFORD, N.J., Dec. 15, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializ...

PRNewsWire - 1 month ago

CRANFORD, N.J., Dec. 9, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializi...

PRNewsWire - 1 month ago

CRANFORD, N.J., Nov. 30, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializ...

PRNewsWire - 2 months ago

CRANFORD, N.J., Nov. 9, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical...

Seeking Alpha - 3 months ago

Citius Pharmaceuticals: Phase 3 Catalyst Countdown And Ready For Take Off

PRNewsWire - 3 months ago

CRANFORD, N.J., Oct. 7, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical...

PRNewsWire - 3 months ago

CRANFORD, N.J., Sept. 30, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commerciali...

PRNewsWire - 3 months ago

CRANFORD, N.J., Sept. 29, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commerciali...

PRNewsWire - 4 months ago

CRANFORD, N.J., Sept. 22, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commerciali...

PRNewsWire - 4 months ago

CRANFORD, N.J., Sept. 15, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.

PRNewsWire - 4 months ago

CRANFORD, N.J., Sept. 8, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.

PRNewsWire - 4 months ago

CRANFORD, N.J., Aug. 26, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.

PRNewsWire - 5 months ago

CRANFORD, N.J., Aug. 13, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.

PRNewsWire - 5 months ago

CRANFORD, N.J., Aug. 10, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.

PRNewsWire - 5 months ago

CRANFORD, N.J., Aug. 5, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.

PRNewsWire - 5 months ago

CRANFORD, N.J., Aug. 5, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.

PRNewsWire - 5 months ago

CRANFORD, N.J., Aug. 4, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.

PRNewsWire - 6 months ago

CRANFORD, N.J., July 22, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.

PRNewsWire - 6 months ago

CRANFORD, N.J., July 20, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc.

PRNewsWire - 6 months ago

CRANFORD, N.J., July 14, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializ...

PRNewsWire - 6 months ago

CRANFORD, N.J., July 13, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and ...

Zacks Investment Research - 6 months ago

Citius Pharmaceuticals (CTXR) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

PRNewsWire - 6 months ago

CRANFORD, N.J., June 29, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializ...

PRNewsWire - 6 months ago

CRANFORD, N.J., June 26, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializ...

PRNewsWire - 7 months ago

CRANFORD, N.J., June 22, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializ...

PRNewsWire - 7 months ago

CRANFORD, N.J., June 2, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializi...

PRNewsWire - 7 months ago

CRANFORD, N.J., May 26, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializi...

PRNewsWire - 8 months ago

CRANFORD, N.J., May 18, 2020 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, t...

Benzinga - 9 months ago

Citius Pharmaceuticals (NASDAQ: CTXR) is trading higher after signing an exclusive option with Novellus to license its Novel Stem-Ce; Therapy for acute respiratory distress syndrome associated...

About CTXR

Citius Pharmaceuticals, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstru... [Read more...]

Industry
Biotechnology
Founded
2007
CEO
Myron Holubiak
Employees
10
Stock Exchange
NASDAQ
Ticker Symbol
CTXR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for CTXR stock is "Buy" and the 12-month stock price forecast is 5.50.

Price Target
$5.50
Analyst Consensus: Buy